Haemonetics

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Haemonetics reports robust Q1 earnings, eyes U.S. growth amid challenges

Haemonetics delivered strong financial performance in Q1 fiscal 2023, driven by robust revenue growth in both the Plasma and Hospital segments. The company's focus on the U.S. market and plans for accelerating growth indicate a positive outlook. However, challenges related to potential cuts in donor payments and varying market conditions outside the U.S. require careful navigation.

Haemonetics Corporation reports robust Q1 fiscal 2024 performance and eyes international expansion

Haemonetics Corporation delivered impressive Q1 fiscal 2024 results, driven by strong revenue growth and improved operating income. The company faces challenges in managing inventory replenishment and potential competition in the autoimmune space. However, opportunities lie in leveraging its robust product portfolio and expanding into international markets.

Haemonetics reports strong Q3 performance, eyes European expansion for growth

Haemonetics delivered robust financial results in Q3, driven by strong revenue growth and strategic initiatives. While facing challenges related to staffing and donor issues, the company is well-positioned to leverage opportunities in expanding markets and technological advancements to drive future growth.

Haemonetics posts robust earnings, eyes global expansion for growth

Haemonetics delivered strong financial results in Q4 2023 and fiscal '23, driven by robust revenue growth and improved earnings per share.
The company's focus on key segments like Plasma, Hospital, Hemostasis, and Vascular Closure positions it well for future growth and market expansion.
While facing challenges such as cost pressures and competitive landscapes, Haemonetics remains optimistic about its ability to drive profitability and market share.
Strategic initiatives, including a modest ramp in market resources and international expansion, present opportunities for Haemonetics to capitalize on market demand and enhance shareholder value.

Haemonetics excels in Q1 '24, eyes growth amid challenges

Haemonetics delivered robust financial performance in Q1 '24, with significant revenue growth and margin expansion.
While facing challenges like product recalls, the company remains focused on value creation and growth acceleration strategies.
Opportunities for growth exist through market scaling, product innovations, and leveraging trial implications for demand growth.

Haemonetics posts robust Q2 earnings, eyes U.S. and international growth

Haemonetics reported strong Q2 results with increased earnings and revenue growth. The company's strategic acquisitions and focus on innovation position it well for future expansion. Challenges in the Blood Center segment require attention, but overall, Haemonetics is poised for continued growth.

Haemonetics posts robust Q3 earnings, eyes growth through innovation

Haemonetics delivered strong financial performance in Q3 2024, driven by revenue growth and operational efficiency improvements.
The company's focus on innovation, technology enhancements, and strategic acquisitions positions it well for future growth and market leadership.
While facing challenges in certain revenue segments, Haemonetics remains poised to capitalize on opportunities for expansion and margin improvement.

Haemonetics posts robust Q4 results, eyes growth through acquisitions

Haemonetics' Q4 2024 performance reflects strong revenue growth and profitability, driven by successful product launches and acquisitions.
While the company faces challenges in margin targets and integration post-acquisitions, strategic focus on innovation and market expansion presents growth opportunities.
Emphasis on non-GAAP measures and regulatory clearances underscores Haemonetics' commitment to transparency and product quality.
Fiscal year 2025 guidance signals a positive outlook for revenue growth and operational efficiency, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Insulet

Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Insulet (PODD). But which of these two stocks presents investors with the better value opportunity right now?

HAE or PODD: Which Is the Better Value Stock Right Now?

Haemonetics Corporation is showing signs of operational momentum again post-pandemic. After a painful 2021, amidst fears of customer losses, Haemonetics Corporation shares and the company have shown a modest recovery again.

Haemonetics Corporation: Premium Blood Play

Investors continue to reward Haemonetics with higher market valuations in 2023. Driving these trends are the firm's attractive underlying economic characteristics.

Haemonetics: Attracting Investment Through Capital Recycling Initiatives

While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings

Financial release accessible online BOSTON , May 11, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal 2023, which ended April 1, 2023, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.

Haemonetics 4th Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website

BOSTON , April 25, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2023 financial results at 6:00 am ET on Thursday, May 11, 2023. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 11, 2023.

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2023 Results: May 11, 2023

BOSTON , April 20, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced the release of its 2022 Corporate Responsibility Report. The report outlines key environmental, social and governance (ESG) initiatives of Haemonetics that align with its core values and corporate strategy.

Haemonetics Publishes Inaugural Corporate Responsibility Report

Kroger

Novo Nordisk

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Haemonetics (HAE), The Kroger Co. (KR), JOYY (YY) and Novo Nordisk (NVO) are poised to gain.

4 Low-Beta Stocks to Buy to Endure Market Volatility

Haemonetics (HAE) could produce exceptional returns because of its solid growth attributes.

Here is Why Growth Investors Should Buy Haemonetics (HAE) Now

The latest development is expected to upgrade Haemonetics' (HAE) Cell Salvage platform and broaden the company's scope in the growing autotransfusion space.

Haemonetics (HAE) Autotransfusion System Gets 510(k) Clearance

BOSTON , March 2, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on the next-generation software for the Cell Saver® Elite®+ Autotransfusion System, with full market release available now. This software upgrade, named Intelligent Control, offers customers key enhancements to help simplify operations, supporting enhanced efficiency and an improved user experience.

Haemonetics Introduces Next Generation "Intelligent Control" Software for Cell Saver® Elite®+ Autotransfusion System

BOSTON , Feb. 27, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 44th Annual Institutional Investors Conference on Monday, March 6, 2023, at 8:40 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at: https://wsw.com/webcast/rj127/hae/1443508.

Haemonetics to Present at Raymond James 44th Annual Institutional Investors Conference

Haemonetics surpassed sell-side expectations with healthy revenue growth from Plasma and Hospital, but margin leverage was lacking due to the ongoing impact of inflation and supply chain issues. The company extended its non-exclusive supply agreement with CSL for another two years, but no terms have been disclosed and CSL revenue is still set to decline as it switches suppliers.

Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer

Leader in blood management for hospitals see estimates and price targets rise after strong quarter

Bull of the Day: Haemonetics (HAE)

Ares Capital

Clarivate Plc

Deutsche Telekom AG

 StoneX Group

SNEX, DTEGY, CLVT, HAE and ARCC have been added to the Zacks Rank #1 (Strong Buy) List on February 10, 2022.

New Strong Buy Stocks for February 10th

In the fiscal third quarter, Haemonetics (HAE) incurs higher research and development costs, primarily due to increased investments in product innovation.

Haemonetics (HAE) Q3 Earnings Beat Estimates, Margins Down

Stryker

Zimmer Biomet Hlds

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, ZBH and HAE are well-poised to gain from the favorable factors.

3 Medical Products Stocks Navigating Industry Challenges

The stock price of Haemonetics Corporation (NYSE: HAE) fell by 5.95% in the most recent trading session. This is why.

HAE Stock: 5.95% Decrease Explanation

Haemonetics Corporation (NYSE:HAE ) Q3 2023 Earnings Conference Call February 7, 2023 8:00 AM ET Company Participants David Trenk - Manager, Investor Relations Chris Simon - Chief Executive Officer Roy Galvin – President, Global Plasma and Blood Center James D'Arecca - Chief Financial Officer Conference Call Participants Drew Ranieri - Morgan Stanley Mike Matson - Needham & Company Joanne Wuensch - Citi Anthony Petrone - Mizuho Andrew Cooper - Raymond James Dave Turkaly - JMP Operator Good day, and welcome to the Haemonetics Third Quarter Fiscal '23 Conference Call and Webcast. At this time, all participants are in a listen-only mode.

Haemonetics Corporation (HAE) Q3 2023 Earnings Call Transcript

Incyte

Incyte stock fell Tuesday after topping quarterly expectations, while fellow medical outlet Haemonetics leapt on its own beat-and-raise. The post Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone appeared first on Investor's Business Daily.

Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone

Haemonetics (HAE) delivered earnings and revenue surprises of 7.59% and 4.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) Q3 Earnings and Revenues Surpass Estimates

Financial release accessible online BOSTON , Feb. 7, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal 2023, which ended December 31, 2022, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.

Haemonetics 3rd Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website

Haemonetics continues to catch a strong bid in FY23' having clipped a 74% gain over the past 12 months. The earnings return on invested capital ultimately justifies this, following HAE's cost restructuring initiatives.

Haemonetics: Earnings Rate Of Change Justifies High Multiples

Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Looking for a Growth Stock? 3 Reasons Why Haemonetics (HAE) is a Solid Choice

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Haemonetics Stock (HAE)